Patents by Inventor Jeffrey L. Bennett

Jeffrey L. Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210301002
    Abstract: This disclosure provides anti-HSPA5 antibodies. Also featured is a method for delivering an agent into the brain, spinal cord, or other component of the central nervous system. In addition, methods of identifying a human subject at risk of relapse of neuromyelitis optica (NMO) or neuropsychiatric systemic lupus erythematosus (NP-SLE) are disclosed, as are methods of determining the severity of an attack of NMO or NP-SLE, and methods of diagnosing NP-SLE.
    Type: Application
    Filed: February 23, 2021
    Publication date: September 30, 2021
    Applicants: Biogen MA Inc., The Regents of the University of Colorado, a body corporate
    Inventors: Jeffrey L. Bennett, Richard M. Ransohoff, Fumitaka Shimizu, Kristin L. Schaller
  • Patent number: 10654916
    Abstract: The present invention is directed to antibodies binding to aquaporin 4 (AQP4) and methods of using such antibodies to treat neuromyelitis optica (NMO) either as a monotherapy or in combination with standard NMO therapies such as immunosuppressives or plasmaphersis.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: May 19, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION, THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE
    Inventors: Jeffrey L. Bennett, Gregory P. Owens, Alan S. Verkman
  • Publication number: 20190330318
    Abstract: This disclosure provides anti-HSPA5 antibodies. Also featured is a method for delivering an agent into the brain, spinal cord, or other component of the central nervous system. In addition, methods of identifying a human subject at risk of relapse of neuromyelitis optica (NMO) or neuropsychiatric systemic lupus erythematosus (NP-SLE) are disclosed, as are methods of determining the severity of an attack of NMO or NP-SLE, and methods of diagnosing NP-SLE.
    Type: Application
    Filed: July 24, 2017
    Publication date: October 31, 2019
    Inventors: Jeffrey L. Bennett, Richard M. Ransohoff, Fumitaka Shimizu, Kristin L. Schaller
  • Publication number: 20140170140
    Abstract: The present invention is directed to antibodies binding to aquaporin 4 (AQP4) and methods of using such antibodies to treat neuromyelitis optica (NMO) either as a monotherapy or in combination with standard NMO therapies such as immunosuppressives or plasmaphersis.
    Type: Application
    Filed: April 23, 2012
    Publication date: June 19, 2014
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION, THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE
    Inventors: Jeffrey L. Bennett, Gregory P. Owens, Alan S. Verkman